MEI Pharma: Best-In-Class P13K Delta Inhibitor Makes Significant Progress In The Clinic

|
About: MEI Pharma, Inc. (MEIP)
by: Jonathan Faison
This article is exclusive for subscribers.
Jonathan Faison
Long only, biotech, event-driven
Summary

Shares have risen by 23% since my initial recommendation and have fallen by 40% since my 2018 post-ASCO update.

I provide a recap of the bullish thesis and recent events.

ME-401 continues to display a promising efficacy and safety profile, and the phase 2 TIDAL study offers an efficient path to market.

Voruciclib looks highly intriguing in addressing an established resistance mechanism to treatment with venetoclax, a drug thought to have $3 billion in peak sales potential.

MEI Pharma is a Buy. One key risk is heavy competition in certain indications being targeted (especially from larger firms with much more in the way of resources).

Shares of MEI Pharma (NASDAQ:MEIP) have risen by 23% since my November 2017 article called the stock a prime turnaround candidate due to multiple material catalysts expected for its oncology-focused pipeline. On the